We are thrilled to announce that Padma Kodukula has joined A-Alpha Bio as Chief Business Officer! Padma will play the invaluable role of overseeing our BD strategy, with a focus on establishing and expanding key drug discovery partnerships. Read more: prweb.com/releases/padma…

Kymera Therapeutics is thrilled to partner with A-Alpha Bio to discover and characterize novel pairs of E3 ubiquitin ligases and high-value therapeutic targets for the rational and prospective design and development of molecular glues.

"The partnership is the first announced by A-Alpha Bio in the cutting-edge and rapidly growing area of targeted protein degradation and leverages the AlphaSeq platform to quantitatively measure protein-protein binding..." Read more below in case you missed our exciting news!

As we prepare for a virtual company-wide retreat tomorrow, we can't help but reminisce on previous in-person team events and how much fun they were...looking forward to the return of more moments like these soon!

We are thrilled to share we've raised $41.5M in our Series B that will grow our team and expand our product portfolio! Thanks to Marshall Wace and Janus Henderson Investors for co-leading the round. Check out the release for even more details hubs.la/Q0149Y620 #singlecell #tech #vc

We are very excited to announce our collaboration with Lawrence Livermore National Laboratory to accelerate antibody discovery for emerging COVID-19 variants by training machine learning models with binding data from AlphaSeq. Read more below! prweb.com/releases/a_alp…

A-Alpha Bio has been selected as a finalist for the annual GeekWire Awards Health Innovation of the Year! It's a fantastic honor to be recognized as a finalist and a testament to the incredible science A-Alpha Bio is doing and our company's progress. geekwire.com/2022/announcin…

A special thank you to our alumni sponsors who participated in previous Genome Startup Day discussions & continue to support our events. We appreciate your contributions to making this an impactful and collaborative community. TwinStrand Biosciences, A-Alpha Bio, @WatchmakerGeno seqWell, Inc.

We are excited to announce our collaboration with Bristol Myers Squibb (Bristol Myers Squibb) to discover molecular glue targets for protein degradation. Read more here: prweb.com/releases/a_alp…

Thank you to Frank Vinluan at MedCity News for featuring our latest collaboration with Bristol Myers Squibb! bit.ly/3wsP6Zz #drugdiscovery #biotech #biopharma #proteindegradation

We’re thrilled to be part of the Top 40 Intelligent Applications created by Madrona, PitchBook, and Goldman Sachs. We'll celebrate next week at the #IA40 Summit sponsored by Microsoft @Amazon.

Applied machine/deep learning & #lifesciences are coming together to transform how we understand & improve life/health. We want to partner w/ teams focused on building wet/dry lab platforms & novel datasets to disrupt traditional drug discovery processes. bit.ly/3FTANT5

It was a pleasure speaking with Chris Picardo from Madrona about A-Alpha Bio and building a company at the intersection of life science and data science. Thank you for featuring A-Alpha Bio in the first Founded and Funded podcast of 2023!

Don't miss our first Founded & Funded of the year! Chris Picardo talks w/ @AAlphabio's David Younger about #ML in #biotech, building business models around data, and when the CEO shouldn't be in the room! Full episode 👉 bit.ly/3IpfxGt What advice do you have for founders?

Excited to announce our latest paper on ML-guided design of single-domain antibodies against CoV-2; A collaboration between Google DeepMind, A-Alpha Bio and Lumen Bioscience.

Excited to share our new paper using AlphaSeq data to enable predictive ML models for antibody engineering with our wonderful collaborators at Google and Lumen Bioscience biorxiv.org/content/10.110…

Check out our new AlphaBind preprint demonstrating our industry-leading antibody optimization model! Also excited to share that we have measured our BILLIONTH protein-protein interaction, providing the crucial training data to predict protein binding. biorxiv.org/content/10.110…